© 2003 European Society of Cardiology
Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure
Kyoto University Graduate School of Medicine 54 kawahara-cho shogoin, Sakyo-ku, Kyoto 606-8507, Japan
* Tel.: +81-75-751-3186; fax: +81-75-751-6477. E-mail address: amat{at}kuhp.kyoyo-u.ac.jp
 |
Abstract |
|---|
Background: Candesartan cilexetil is a new angiotensin II receptor blocker with a high affinity for the angiotensin II-subtype 1 receptor.
Aims: This 6-month study examined the safety and efficacy of candesartan cilexetil, 8 mg once daily, to prevent the progression of congestive heart failure (CHF).
Methods: This randomised, double-blind, placebo-controlled study enrolled 305 patients with CHF who were not receiving ACE inhibitor therapy. The composite primary efficacy endpoint was progression of CHF or addition or dose escalation of CHF medications. The secondary endpoints were incidence of cardiovascular events and changes in left ventricular function.
Results: The study was prematurely terminated after the second interim safety analysis. The incidence of confirmed progression of CHF was significantly lower in the candesartan group (7.4%) than in the placebo group (22.2%), with a risk reduction of 66.7% and a risk difference of –14.8% (95% CI: –22.8 to –6.8%, P<0.001). Cardiovascular events were also significantly lower during treatment with candesartan than with placebo (10.8% vs. 22.9%) with a risk reduction of 52.8% and a risk difference of –12.1% (95% CI: –20.6 to –3.6%, P<0.01). The actively treated group had a significant improvement in hemodynamics. Candesartan cilexetil was well tolerated.
Conclusion: Candesartan cilexetil, 8 mg/day, significantly reduced the progression of CHF when compared with placebo.
Key Words: Candesartan cilexetil • Congestive heart failure • Randomised study • RAS inhibition
Received July 19, 2002; Revised July 3, 2003; Accepted September 11, 2003
All ARCH-J Study Investigators are listed in the Appendix.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. T. Tsuyuki and M. A. McDonald Response to Tsuyuki and McDonald Circulation, August 22, 2006; 114(8): 855 - 860. [Full Text] [PDF]
|
|
|
|
 |
|
 Additional Information JAMA, November 2, 2005; 294(17): E1 - E3. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A McDonald, S. H Simpson, J. A Ezekowitz, G. Gyenes, and R. T Tsuyuki Angiotensin receptor blockers and risk of myocardial infarction: systematic review BMJ, October 15, 2005; 331(7521): 873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Lee, D. C. Rhew, M. Dylan, E. Badamgarav, G. D. Braunstein, and S. R. Weingarten Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction Ann Intern Med, November 2, 2004; 141(9): 693 - 704. [Abstract] [Full Text] [PDF]
|
|